Abstract
Although chlorpromazine was the first synthetic neuroleptic drug discovered and represented a major innovation in the therapy of psychoses, its use was eroded by later generations of more potent phenothiazine drugs and, in particular, by the nonphenothiazine, haloperidol. In the two decades between 1958 and 1978, haloperidol became one of the most frequently prescribed neuroleptics in the world (Ayd, 1978) and the World Health Organization listed it, along with chlorpromazine and fluphenazine, as an essential psychotherapeutic drug (WHO, 1979).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Ayd, F. J., Jr.: Haloperidol: Twenty years’clinical experience. J. Clin. Psychiatry 39:807–814, 1978.
Baldessarini, R. J.: Drugs and the treatment of psychiatric disorders, in The Pharmacological Basis of Therapeutics, 7th Ed., A. G. Gilman, L. S. Goodman, T. W. Rail, and F. Murad, eds., pp. 387–445, Macmillan, New York, 1985.
Ban, T. A.: Haloperidol and the butyrophenones. Psychosomatics 14:286–297, 1973.
Ban, T. A. and Pecknold, J. C.: Haloperidol in the therapy of severe behavior disorders. Curr. Psychiatr. Ther. 16:127–137, 1976.
Bennett, D. R., ed.: Antipsychotic drugs, in AMA Drug Evaluations, 5th Ed., pp. 235–237, American Medical Association, Chicago, 1983.
Charpentier, P., Gailliot, P., Jacob, R. M., Gaudechon, J., and Buisson, P.: Recherches sur les dimethylaminopropyl-JV-phenothiazines substitutee. Comptes Rendus Chimie Organique 235:59,60,1952.
Crane, G. E.: A review of clinical literature on haloperidol. Int. J. Neuro-psychiatr. 3: S110–S123, 1967.
Delay, J. and Deniker, P.: Caractéristiques psycho-physiologiques des médicaments neuroleptiques, in Psychotropic Drugs, S. Garattini and V. Ghetti, eds., pp. 486–501, Elsevier, Amsterdam, 1957.
Delay, J., Deniker, P., and Harl, J. M.: Utilization en therapeutique psychiatrique d’une phenothiazine d’action central elective (4560 R.P.) Ann. Méd.-Psychol. (Paris) 110:112–117, 1952a.
Delay, J. Deniker, P., and Harl, J. M.: Traitaient des etats d’excitation et d’agitation par une methode medicamenteuse dérivee de l’hiberno-therapie. Ann. Méd.-Psychol. (Paris) 110:267–273, 1952b.
Delay, J., Pichot, P., Lempériére, T. and Elissalde, B.: Halopéridol et chimiothérapie des psychoses. Presse Méd. 68:1353–1355, 1960.
Divry, P., Bobon, J., and Collard, J.: Le “R1625”: Nouvelle thérapeutique symptomatique de l’agitation psychomotrice. Ada Neurol. Psychiatr. Belg. 58:878,888,1958.
Divry, P., Bobon, J., and Collard, J.: Rapport sur l’activite neuro-psycho-pharmacologique du halopéridol (RI625). Ada Neurol. Belg. 60: 7–19, 1960.
Divry, P., Bobon, J., Collard, J., Pinchard, A., and Nols, E.: Etude et expérimentation cliniques du RI625 on haloperidol, nouveau neuroleptique et “neurodysleptique.” Ada Neurol. Psychiatr. Belg. 59:337–366, 1959.
Eisleb, O. and Schaumann, O.: Dolantin, ein neuartiges Spasmolytikum und Analgetikum. Dtsch. Med. Wochenschr. 65:967,968,1939.
Goldstein, B. J., ed.: Halopéridol. Int. J. Neuropsychiatr. 3: S1–S153, 1967.
Goldstein, B. J., Clyde, D. J., and Caldwell, J. M.: Clinical efficacy of the butyrophenones as antipsychotic drugs, in Psychopharmacology, A Review of Progress, 1957-1967 (Public Health Service Publication No. 1836, D. H. Efron, ed., US Gov’t. Printing Office, Washington, DC, 1968.
Hollister, L. E.: Clinical Pharmacology of Psychotherapeutic Drugs, 2nd Ed., Churchill Livingstone, New York, 1983.
Janssen, P. A.: The butyrophenone story, in Discoveries in Biological Psychiatry, F. J. Ayd and B. Blackwell, eds., pp. 165–179, J. B. Lippincott, Philadelphia, 1970.
Janssen, P. A. and Tollenaere, J. P.: The discovery of the butyrophenone-type neuroleptics, in Discoveries in Pharmacology, vol. 1, M. J. Parnham and J. Bruinvels, eds., pp. 181–196, Elsevier, Amsterdam, 1983.
Janssen, P. A., Jageneau, A. H., Van Proosdij-Hartzema, E. G., and Dejongh, D. K.: The pharmacology of a new potent analgesic, R951 2 [N-(4-car-bethoxy-4-phenyl)-piperidino]-propiophenone HC1. Ada Physiol. Pharmacol. Neerl. 7:373–02, 1958.
Janssen, P. A., Van de Westeringh, C., Jageneau, A. H., Demoen, P. J. Hermans, B. K., Van Daele, G. H., Schellekens, K. H., Van der Eycken, C. A., and Niemegeers, C. J.: Chemistry and pharmacology of CNS depressants related to 4-(4-hydroxy-4-phenylpiperidino)butyrophenone. Part I—Synthesis and screening data in mice. J. Med. Pharmaceut. Chem. 1:281–297, 1959a.
Janssen, P. A., Jageneau, A. H., Demoen, P. J. Van de Westeringh, C., Raeymaekers, A. H., Wouters, M. S., Sanczuk, S., Hermans, B. K., and Loomans, J. L.: Compounds related to pethidine. I. Mannich bases derived from norpethidine and acetophenones. J. Med. Pharmaceut. Chetn. 1:105–120, 1959b.
Müller, J. M., Schüttler, E., and Bein, H. J.: Reserpin, der sedative Wirkstoff aus Rauwolßa serpentina. Experientia 8:338, 1952.
Paquay, J., Arnould, F., and Burton, P.: Etude clinique de l’action du R1625 â doses modérées en psychiatrie. Ada Neurol. Belg. 59:882–891, 1959.
Steck, H.: Le syndrome extra-pyramidal et diencéphalique au cours des traitments au Largactil et du Serpasil. Ann. Méd.-Psychol. (Paris) 112(2): 737–743, 1954.
World Health Organization: The selection of essential drugs; Second report of the WHO Expert Committee (Technical Report Series, 641 ), World Health Organization, Geneva, 1979.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 1990 Springer Science+Business Media New York
About this chapter
Cite this chapter
Maxwell, R.A., Eckhardt, S.B. (1990). Haloperidol. In: Drug Discovery. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-4612-0469-5_9
Download citation
DOI: https://doi.org/10.1007/978-1-4612-0469-5_9
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-4612-6775-1
Online ISBN: 978-1-4612-0469-5
eBook Packages: Springer Book Archive